Text Size

Correction to: Multicenter, Randomized, Controlled Study Comparing Tafluprost/Timolol Fixed Combination with Latanoprost/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension (Advances in Therapy, (2018), 35, 6, (796-808), 10.1007/s12325-018-0718-9)

Suzuki K., Otsuka N., Hizaki H., Hashimoto M., Kuwayama Y., On behalf of the Tafluprost/Timolol Versus Latanoprost/Timolol (TTVLT) Study Group


  • 2019
  • Advances in Therapy
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    Suzuki Eye Clinic, Yamaguchi, Japan; Santen Pharmaceutical Co., Ltd., Osaka, Japan; Fukushima Eye Clinic, Osaka, Japan

Related Publications

An Exploratory Study of Machine Learning-Based Open-Angle Glaucoma Detection Using Specific Autoantibodies

Takada N., Ishikawa M., Ninomiya T., Izumi Y., Sato K., Kunikata H., Yokoyama Y., Tsuda S., Fukuda E., Yamaguchi K., Ono C., Kirihara T., Shintani C., Hanyuda A., Goshima N., Zorumski C.F., NakazawaT.


Relaxation of Precontracted Ciliary Artery and Ciliary Muscle In Vitro by Kinin Peptides: Relevance to Retinal Blood Flow and Intraocular Pressure Regulation

Sharif N.A., Kulkarni-Chitnis M., Okolie A., Chaudhry S.D., Njie-Mbye Y.F., Ohia S.E.


The Role of EP3 Agonism in Intraocular Pressure-Lowering by Sepetaprost, a Novel Dual Agonist of FP and EP3 Receptors, in Monkeys

Maki K., Kimura E., Yamamoto Y., Fuwa M., Toris C.B., Fan S., Shimazaki A., Kato M.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022